rpl23-A Antibody

What is RPL23A and what are its key molecular characteristics?

RPL23A is a 60S ribosomal protein with a molecular weight of approximately 15 kDa and consists of 156 amino acids . It is a crucial component of the large 60S subunit of ribosomes, the organelles that catalyze protein synthesis . The protein sequence is remarkably conserved, with 100% sequence homology between mice and humans, highlighting its evolutionary importance . RPL23A has gained particular research interest due to its identification as a target antigen in autoimmune conditions like rheumatoid arthritis . The protein contains several distinct domains and epitopes that can be targeted by different antibodies, with commercially available antibodies recognizing various regions including amino acids 59-156 .

What expression patterns does RPL23A exhibit across different tissues?

RPL23A demonstrates ubiquitous expression across human and mouse tissues, consistent with its fundamental role in ribosomal function and protein synthesis . In mouse models, high levels of RPL23A mRNA have been detected across various organs . Similarly, in human tissues, RPL23A mRNA is expressed universally . In rheumatoid arthritis and osteoarthritis synovial tissues, RPL23A protein has been specifically detected in the cytoplasm of synovial cells, including CD55+ fibroblast-like synoviocytes (FLSs) . This widespread expression pattern makes RPL23A an interesting target for studying both normal cellular function and potential pathogenic mechanisms in autoimmune disorders.

What are the standard applications for RPL23A antibodies in research?

RPL23A antibodies have been validated for multiple experimental applications with specific recommended protocols:

For optimal results in immunohistochemistry, antigen retrieval with TE buffer (pH 9.0) is recommended, with citrate buffer (pH 6.0) as an alternative . It is critical to note that experimental conditions should be optimized for each application as sensitivity may vary depending on sample type and preparation method .

How should researchers select the appropriate RPL23A antibody for their specific application?

Selection of the optimal RPL23A antibody depends on several factors. First, researchers should consider the target species; commercially available antibodies show reactivity with human, mouse, and rat samples . Second, the experimental application is crucial - different antibodies perform optimally in different techniques (WB, IHC, IF, etc.) . Third, researchers should consider the epitope of interest; antibodies targeting different regions of RPL23A (e.g., AA 1-92, AA 59-156, AA 111-140) are available . Finally, the clonality of the antibody (monoclonal vs. polyclonal) should be selected based on experimental needs - monoclonal antibodies provide higher specificity for a single epitope, while polyclonal antibodies may offer greater sensitivity by recognizing multiple epitopes .

How can RPL23A antibodies be utilized in autoimmune disease research?

RPL23A antibodies have significant applications in autoimmune disease research, particularly for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Research has shown that a substantially higher proportion of RA patients (16.8%, n=374) tested positive for serum anti-RPL23A IgG autoantibodies compared to healthy controls (1.3%, n=74) . To investigate this phenomenon, researchers can employ RPL23A antibodies to:

• Detect RPL23A expression in synovial tissues through immunohistochemistry or immunofluorescence

• Isolate and quantify anti-RPL23A autoantibodies from patient sera through immunoprecipitation and ELISA

• Analyze T-cell responses to RPL23A through in vitro stimulation assays

• Investigate the co-localization of RPL23A with other markers of inflammation in affected tissues

These approaches can help elucidate the role of RPL23A in driving autoimmune pathology and potentially identify novel therapeutic targets .

What methodologies can detect RPL23A-reactive T cells in clinical samples?

Detection of RPL23A-reactive T cells in clinical samples requires specialized techniques:

• Ex vivo stimulation assays: Synovial fluid or peripheral blood mononuclear cells can be isolated from patients and stimulated with recombinant RPL23A protein. T-cell activation can be measured through cytokine production (particularly IFN-γ) using flow cytometry, ELISA, or ELISpot assays .

• MHC-dependent blocking assays: To confirm specificity, anti-MHC class II blocking antibodies (such as anti-I-A/E) can be used during stimulation to verify that T-cell responses are indeed MHC class II-dependent .

• Cytokine profiling: In RA patients, CD4+ T cells from synovial fluid may produce IFN-γ upon RPL23A stimulation. This can be measured through intracellular cytokine staining followed by flow cytometry analysis .

• T-cell proliferation assays: CFSE-labeled T cells co-cultured with RPL23A can reveal antigen-specific proliferation through flow cytometry.

Research has demonstrated that RPL23A-specific T-cell responses can be detected in synovial fluid from a subset of RA patients, suggesting a potential pathogenic role in disease development .

How does RPL23A interact with the MHC class II pathway in autoimmune contexts?

RPL23A interaction with the MHC class II pathway is crucial for understanding its role in autoimmunity. Experimental evidence indicates that RPL23A can stimulate T cells in a class II MHC I-Ad dependent manner, as demonstrated in mouse models . When investigating this interaction:

• Peptide mapping: Studies have identified specific RPL23A peptides (such as RPL23A 71-90) that most potently stimulate T-cell receptors in experimental models .

• MHC blocking experiments: Using anti-MHC class II blocking antibodies substantially reduces IL-17A production by RPL23A-stimulated lymphocytes, confirming MHC class II dependency .

• Dose-response relationship: Recombinant RPL23A protein stimulates T-cell hybridoma cells in a dose-dependent manner that requires MHC class II presentation .

This MHC class II-dependent presentation of RPL23A-derived peptides to CD4+ T cells appears to drive differentiation into arthritogenic effector T helper cells, capable of mediating arthritis even in the presence of regulatory T cells .

What are optimal conditions for Western blot detection of RPL23A?

For successful Western blot detection of RPL23A, researchers should follow these methodological guidelines:

• Sample preparation: Total protein extraction should be performed using standard lysis buffers containing protease inhibitors to prevent degradation. RPL23A has been successfully detected in various cell lines including BxPC-3, PC-3, Jurkat, and NIH/3T3 cells .

• Protein loading and separation: Load 20-40 μg of total protein per lane on a 12-15% SDS-PAGE gel, as RPL23A is a relatively small protein (15 kDa) .

• Transfer conditions: Use PVDF membrane and standard transfer protocols (100V for 1 hour or 30V overnight at 4°C).

• Antibody dilution: Primary RPL23A antibody should be diluted between 1:500-1:2000 in blocking buffer (5% non-fat milk or BSA in TBST) .

• Incubation parameters: Incubate with primary antibody overnight at 4°C, followed by appropriate HRP-conjugated secondary antibody.

• Detection system: Enhanced chemiluminescence (ECL) detection systems are suitable for visualizing RPL23A bands.

• Expected molecular weight: The observed molecular weight should be approximately 15 kDa .

If non-specific bands appear, further optimization of blocking conditions or antibody dilutions may be necessary.

What controls should be included when validating RPL23A antibodies?

Proper validation of RPL23A antibodies requires several critical controls:

• Positive tissue/cell controls: Include samples known to express RPL23A, such as BxPC-3, PC-3, Jurkat, or NIH/3T3 cells for Western blotting; human or mouse brain tissue for immunohistochemistry .

• Negative controls: Include isotype-matched control antibodies to rule out non-specific binding.

• Knockdown/knockout validation: For definitive validation, compare results between wild-type samples and those with RPL23A knockdown or knockout. Published literature includes at least 3 studies using this approach to verify antibody specificity .

• Peptide competition assay: Pre-incubate the RPL23A antibody with purified recombinant RPL23A or the immunogen peptide sequence prior to the experiment. Signal reduction confirms specificity.

• Cross-reactivity assessment: If studying non-human samples, verify cross-reactivity with the species of interest, as some RPL23A antibodies may show different reactivity patterns across species .

• Multiple antibody verification: When possible, validate findings using multiple antibodies targeting different epitopes of RPL23A to ensure consistent results .

These controls are essential for establishing the reliability and specificity of experimental findings involving RPL23A antibodies.

How should samples be prepared for immunohistochemical detection of RPL23A?

Successful immunohistochemical detection of RPL23A requires careful sample preparation:

• Fixation: Formalin-fixed, paraffin-embedded (FFPE) tissues are typically used, with 10% neutral buffered formalin being the standard fixative.

• Antigen retrieval: This critical step is required to unmask epitopes. For RPL23A, the recommended protocol is:

  • Primary method: TE buffer at pH 9.0

  • Alternative method: Citrate buffer at pH 6.0

• Blocking: Block endogenous peroxidase activity with 3% hydrogen peroxide, followed by protein blocking with 5-10% normal serum.

• Antibody dilution: Dilute RPL23A antibody 1:50-1:500 depending on the specific antibody and sample type .

• Incubation parameters: Incubate with primary antibody overnight at 4°C or for 1-2 hours at room temperature.

• Detection system: Use appropriate detection systems such as HRP-polymer with DAB substrate or fluorescence-based methods.

• Counterstaining: For brightfield microscopy, hematoxylin counterstaining helps visualize tissue architecture.

RPL23A has been successfully detected in human brain tissue and synovial tissues using these techniques . In synovial tissues from RA and osteoarthritis patients, RPL23A was detected in the cytoplasm of synovial cells, including CD55+ fibroblast-like synoviocytes .

How should researchers interpret anti-RPL23A autoantibody data in patient samples?

Interpretation of anti-RPL23A autoantibody data requires careful consideration of several factors:

• Establishing threshold values: Research has established clear cutoff values for positivity, with 16.8% of RA patients (n=374) testing positive for anti-RPL23A IgG autoantibodies compared to only 1.3% of healthy controls (n=74) . These values should guide interpretation of results in new studies.

• Disease specificity analysis: Compare autoantibody prevalence across different conditions. For instance, while 16.8% of RA patients showed anti-RPL23A positivity, the rates were different in other conditions: 8.7% in psoriatic arthritis (PsA) (n=23), 0% in osteoarthritis (OA) (n=11), 0% in systemic lupus erythematosus (SLE) (n=30), and 0% in polymyositis/dermatomyositis (PM/DM) (n=10) .

• Correlation with clinical parameters: Analyze relationships between anti-RPL23A antibody titers and clinical parameters such as disease duration, activity scores, and treatment response.

• Citrullination considerations: Unlike some other RA-associated autoantibodies, research has shown no significant difference in antibody titers whether assessed with citrullinated or non-citrullinated RPL23A protein . This distinguishes anti-RPL23A responses from classical anti-citrullinated protein antibodies (ACPAs).

• Longitudinal analysis: When possible, evaluate antibody titers over time to assess correlation with disease progression or treatment response.

This multi-faceted approach to data interpretation allows for more comprehensive understanding of the role of anti-RPL23A responses in autoimmune pathology.

What should researchers consider when analyzing RPL23A-reactive T-cell responses?

Analysis of RPL23A-reactive T-cell responses requires careful experimental design and data interpretation:

• Cytokine profile characterization: Beyond simple detection, researchers should characterize the complete cytokine profile of responding T cells. In experimental models, RPL23A stimulation can drive T cells to produce IL-17A in an MHC class II-dependent manner . In human RA patients, CD4+ T cells producing IFN-γ in response to RPL23A have been detected .

• Frequency analysis: Quantify the frequency of RPL23A-responsive T cells within the total CD4+ population using flow cytometry or ELISpot assays.

• Peptide specificity mapping: Determine which specific regions of RPL23A elicit the strongest T-cell responses. In mouse models, the RPL23A 71-90 peptide has been identified as stimulating T-cell receptors most potently .

• MHC dependency verification: Include MHC blocking controls to confirm that observed responses are antigen-specific and MHC-restricted. Experiments with anti-MHC class I or class II (anti-I-A/E) blocking antibodies can reveal whether responses are primarily CD8+ or CD4+ T-cell mediated .

• Correlation with antibody responses: Analyze whether T-cell reactivity correlates with anti-RPL23A antibody titers in the same patients, which would suggest coordinated T and B cell responses against this antigen.

These analytical approaches can help distinguish pathogenic from non-pathogenic T-cell responses and clarify the role of RPL23A in disease mechanisms.

What is the current understanding of RPL23A's role in autoimmune disease pathogenesis?

The current understanding of RPL23A in autoimmune disease pathogenesis centers on several key findings:

• Autoantibody target: RPL23A has been identified as a target of autoantibodies in a significant subset of rheumatoid arthritis patients (16.8%) . This suggests it may serve as a biomarker for a specific disease subset.

• T-cell responses: CD4+ T cells from RA patient synovial fluid can produce IFN-γ upon stimulation with RPL23A, indicating active T-cell responses against this self-protein .

• MHC class II presentation: RPL23A-derived peptides can be presented via MHC class II molecules, stimulating CD4+ T cells in a dose-dependent manner . This process is crucial for the development of autoimmunity.

• Conservation across species: The 100% sequence conservation between human and mouse RPL23A has facilitated translational research using mouse models .

• Potential pathogenic mechanism: In mouse models, RPL23A-specific T cells can differentiate into arthritogenic effector T helper cells capable of mediating arthritis even in the presence of regulatory T cells .

• Disease specificity: Anti-RPL23A responses appear more common in RA (16.8%) and psoriatic arthritis (8.7%) than in other autoimmune conditions like SLE or PM/DM (0%) , suggesting some disease specificity.

These findings collectively suggest that in a subset of patients, immune responses against this ubiquitously expressed ribosomal protein may contribute to disease pathogenesis, potentially through breaking of tolerance to a self-protein that is normally sequestered from the immune system.

How might targeting RPL23A-specific immune responses be developed as a therapeutic strategy?

Targeting RPL23A-specific immune responses represents a potential therapeutic avenue that could be developed through several approaches:

• Antigen-specific immunotherapy: Development of tolerogenic vaccines or peptides based on immunodominant regions of RPL23A (such as the RPL23A 71-90 peptide identified in mouse models) could potentially induce tolerance rather than immunity.

• T-cell receptor targeting: Identifying and blocking T-cell receptors specifically recognizing RPL23A-derived peptides might inhibit pathogenic T-cell activation.

• MHC class II blockade: Since RPL23A stimulation of T cells is MHC class II-dependent , targeted blocking of specific MHC class II-peptide interactions could inhibit pathogenic T-cell activation.

• B-cell depletion therapy: For patients with high anti-RPL23A antibody titers, B-cell depleting therapies might be particularly effective in reducing autoantibody production.

• Cytokine-targeted therapy: Blocking cytokines produced by RPL23A-specific T cells (such as IL-17A or IFN-γ) may inhibit downstream inflammation .

• Patient stratification: RPL23A reactivity could serve as a biomarker to stratify patients for clinical trials, potentially identifying subsets most likely to respond to specific immunomodulatory therapies.

Research in this direction is still in early stages, but the identification of RPL23A as a target antigen in autoimmune conditions provides a foundation for developing more targeted therapeutic approaches for specific patient subsets.

What emerging technologies are advancing RPL23A research in autoimmunity?

Several cutting-edge technologies are driving advances in understanding RPL23A's role in autoimmunity:

• Single-cell RNA sequencing: This technology allows characterization of gene expression patterns in individual cells, facilitating identification of cell populations expressing or responding to RPL23A.

• T-cell receptor (TCR) sequencing: Deep sequencing of TCR repertoires from patients can identify expanded clones potentially reactive against RPL23A-derived peptides.

• Protein-protein interaction mapping: Advanced proteomics techniques can map the interactome of RPL23A beyond its ribosomal functions, potentially revealing novel roles in immune signaling.

• CRISPR-Cas9 gene editing: This technology enables precise manipulation of RPL23A expression or sequence in experimental models to study functional consequences.

• HLA tetramer technology: Construction of MHC class II tetramers loaded with RPL23A peptides allows direct identification and isolation of antigen-specific T cells from patient samples.

• Mass cytometry (CyTOF): This technique permits simultaneous assessment of multiple cellular parameters, enabling comprehensive phenotyping of RPL23A-responsive immune cells.

• Humanized mouse models: Development of mice expressing human MHC molecules can better recapitulate human immune responses to RPL23A, bridging the translational gap.

These technologies collectively provide unprecedented capabilities for dissecting the complex immunological mechanisms underlying autoimmune responses to RPL23A, potentially leading to more precise diagnostic and therapeutic approaches for conditions like rheumatoid arthritis.